Comparative Pharmacology
Head-to-head clinical analysis: NITRO IV versus RECTIV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NITRO IV versus RECTIV.
NITRO IV vs RECTIV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitroglycerin is a vasodilator that primarily acts by relaxing vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase to increase cGMP, leading to venodilation and, at higher doses, arterial dilation. This reduces preload and afterload, decreasing myocardial oxygen demand.
RECTIV (nitroglycerin) is a nitric oxide (NO) donor that relaxes vascular smooth muscle via stimulation of intracellular cyclic guanosine monophosphate (cGMP) production, leading to vasodilation. In chronic anal fissures, it reduces internal anal sphincter pressure and improves blood flow to the anoderm.
Initial infusion rate 5 mcg/min via continuous IV infusion, titrate by 5 mcg/min every 3-5 minutes until response; usual maintenance dose 10-20 mcg/min; maximum 200 mcg/min.
1 gram (0.5 mg nitroglycerin) applied intrarectally as an ointment 10-15 minutes before anticipated bowel movement, up to twice daily.
None Documented
None Documented
1-4 minutes (rapidly cleared from blood); terminal half-life ~2-3 minutes due to rapid biotransformation in RBCs and vascular tissue.
Terminal elimination half-life is approximately 2-4 hours in healthy adults. In patients with severe hepatic impairment, half-life may be prolonged up to 8-10 hours, requiring dose adjustment.
Renal (minimal, <1% unchanged) and hepatic metabolism; metabolites excreted renally.
Primarily renal; approximately 60-70% of the parent drug and metabolites excreted in urine within 24 hours. Fecal elimination accounts for ~20-30% via biliary secretion. Less than 1% unchanged drug recovered in feces.
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator